A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Prostate Cancer
Interventions
DRUG

galeterone

Trial Locations (23)

10029

Mount Sinai, New York

14263

Roswell Park Center Institute, Buffalo

21201

University of Maryland, Baltimore

21205

Sidney Kimmel Johns Hopkins, Baltimore

21401

AAHS Research Institute, Annapolis

28025

Carolina Clinical Trials, Concord

29572

Carolina Urologic Research Center, Myrtle Beach

29605

Greenville Hospital System University Medical Center, Greenville

33486

Raton Regional Hospital, Lynn Cancer Institute, Boca Raton

48201

Karmanos Cancer Institute, Detroit

68130

Urology Cancer Center and GU Research Network, Omaha

70112

Tulane Cancer Center, New Orleans

75230

Urology Clinics of North Texas, Dallas

92404

San Bernardino Urological Associates, San Bernardino

98136

University of Washington/Seattle Cancer Care Alliance, Seattle

90095-7384

UCLA David Geffen School of Medicine, Los Angeles

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

08724

Coastal Urology Associates, Brick

08648

Premier Urology Associates, LLC, Lawrenceville

V5Z 4E6

BC Cancer Agency, Vancouver

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

Sponsors
All Listed Sponsors
lead

LTN PHARMACEUTICALS, INC.

INDUSTRY